• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Stroke. Author manuscript; available in PMC Jul 1, 2010.
Published in final edited form as:
PMCID: PMC2704252
NIHMSID: NIHMS114450

Beta-amyloid, blood vessels and brain function

Eric E. Smith, MD, MPH1 and Steven M. Greenberg, MD, PhD2

Abstract

Cerebrovascular disease and Alzheimer’s disease are common diseases of aging and frequently co-exist in the same brain. Accumulating evidence suggests that the presence of brain infarction, including silent infarction, influences the course of Alzheimer’s disease. Conversely, there is evidence that beta-amyloid can impair blood vessel function. Vascular beta-amyloid deposition, also known as cerebral amyloid angiopathy, is associated with vascular dysfunction in animal and human studies. Alzheimer’s disease is associated with morphological changes in capillary networks, and soluble beta-amyloid produces abnormal vascular responses to physiologic and pharmacologic stimuli. In this review we discuss current evidence linking beta-amyloid metabolism with vascular function and morphological changes in animals and humans.

Keywords: Alzheimer’s disease, cerebral amyloid angiopathy, vascular cognitive impairment

REVIEW

Medical advances leading to increased life expectancy are causing rapid changes in the medical epidemiology of the elderly. Of major concern is whether gains in years of life will be matched by equal gains in quality of life. Preservation of cognitive function is particularly important. The incidence of dementia and stroke rises exponentially with age. Men at age 65 have a greater than one in four chance of developing stroke, dementia or both, and women at age 65 have a greater than one in three chance of developing stroke, dementia or both.1 The prevalence of cognitive impairment is even greater when including forms of impairment short of dementia.2

Alzheimer’s disease (AD) and cerebrovascular disease are two common pathologies of aging and are the most frequent contributors to cognitive dysfunction. Rather than acting separately, it is now recognized that these pathologies are frequently present in the same brain,3, 4 both demented and non-demented. Autopsy studies suggest that small “silent” infarcts contribute to cognitive impairment,5 and most studies show a significant effect beyond the effects attributable to AD pathology alone.6-8 Clearly there is an urgent need to decipher the relationship between AD and cerebrovascular disease, and how they lead to cognitive impairment. Possible links between cerebrovascular pathology and AD pathology have previously been reviewed (for example, by de la Torre).9 Here, we specifically review evidence linking parenchymal and vascular beta-amyloid with morphological changes and dysfunction of vessel wall components, with a focus on recent animal and human studies.

A link between ABeta and vascular disease is most clearly demonstrated in the case of cerebral amyloid angiopathy (CAA), where deposition of ABeta in the vascular media and adventitia leads to loss of integrity of the vessel wall with resulting brain hemorrhages, both large and small. Well recognized as a cause of brain hemorrhage, CAA is now increasingly recognized as a probable cause of brain ischemia and cognitive impairment independent of stroke.10 Additionally, recent evidence links beta-amyloid with impaired blood vessel morphology and function in the absence of deposition in the vascular media.

Beta-amyloid is produced by proteolytic cleavage of the amyloid precursor protein (APP) by alpha-secretase and gamma-secretase. Cleavage by these enzymes yields a family of ABeta peptides, with a 40-amino acid species (ABeta40) and 42 amino-acid species (ABeta42) predominating. ABeta accumulates in the interstitial fluid in correlation with the degree of synaptic activity.11 These peptides may undergo a number of fates (Figure 1).12 They may be degraded by other proteolytic enzymes including neprilysin and insulin degrading enzyme. They may remain in solution and enter the plasma via perivascular drainage pathways,13 or efflux across the blood-brain barrier.14 Or they may polymerize to form soluble oligomers or insoluble amyloid fibrils with deposition in the brain parenchyma as senile plaques, as seen in AD, or the vascular media and adventitia, as seen in CAA. In AD both soluble oligomers and insoluble plaques have been proposed to play a role in neuronal dysfunction.15 Here, we review current evidence on the effects of soluble and deposited ABeta on brain blood vessel integrity and function.

Figure 1
Beta-amyloid (Aβ) production and clearance. Amyloid precursor protein (APP) undergoes proteolytic cleavage by alpha- and gamma-secretase to yield a 40 amino acid fragment (Aβ40) or 42 amino acid fragment (Aβ42). Possible fates ...

Cerebral amyloid angiopathy

Initially recognized in the context of co-existing AD, it was not until the 1970s that CAA was recognized as a major cause of lobar intracerebral hemorrhage.16, 17 The in vivo diagnosis of CAA rests on the demonstration of single or multiple lobar hemorrhages or microbleeds without other evident cause.18 Sporadic and some forms of familial CAA are characterized by deposition of beta-amyloid in the media and adventitia of small arteries and capillaries of the leptomeninges and cerebral cortex. White matter vessels are much less affected, and the occipital regions are heavily affected, for unclear reasons.19 In contrast to AD, the predominant ABeta species in vascular deposits is the relatively more soluble Aβ40. Although the exact source of vascular amyloid is unknown, it is believed that ABeta is predominantly generated by neurons and then deposited in the vessel wall.20

Numerous pathological studies have demonstrated histological19 and ultrastructural21 abnormalities of the vessel wall in CAA. Loss of smooth muscle cells occurs with replacement of the vascular media by amyloid. There is a direct toxic effect of wild-type and mutant forms of ABeta, as demonstrated in cell culture studies.20, 22 In addition recent research using animal models suggests that vascular amyloid decreases adhesion of vascular smooth muscle cells to the basement membrane23 and that capillary amyloid deposition may be associated with capillary occlusion.24

These observations of smooth muscle degeneration and capillary occlusion raise the question of whether cerebral blood flow regulation, dependent on normal vascular endothelial and smooth muscle activity, is impaired in CAA. Indeed, an animal model of CAA shows decreased cortical vascular reactivity to carbon dioxide and whisker stimulation in proportion to the severity of vascular amyloid.25

The concept that CAA alters blood flow is further supported by pathologic studies showing an increased prevalence of ischemic lesions in brains with CAA and clinical studies showing that CAA is associated with cognitive impairment independent of the presence of brain hemorrhage, at least partly attributable to ischemia.10 Case-control pathology studies, predominantly performed in brains with a concomitant clinical diagnosis of AD, suggest that severe CAA is associated with small cerebral infarcts independent of age, hypertension or apolipoprotein E genotype.26-29 The association is particularly strong for microinfarctions, consistent with the involvement by CAA of small arteries and capillaries. In addition, case series show that white matter demyelination, presumably ischemic, may occur.30-32 The severity of CAA has been associated with increased odds of antemortem dementia,33 and worse performance on cognitive tests in persons with concomitant AD,34 in population-based autopsy studies that simultaneously controlled for severity of AD pathology.

MRI and CT are insensitive to microinfarctions but are arguably more sensitive than autopsy to the presence of white matter lesions. Studies of consecutive patients with CAA presenting with brain hemorrhage show that CT or MRI white matter lesions are common,35 of greater severity than in healthy aging,36 and are associated with cognitive impairment independent of the effects of the brain hemorrhage.35 Familial forms of ABeta CAA also show extensive white matter lesions.37 Newer MRI measurements of water proton diffusion are sensitive to subtle alterations in tissue microarchitecture and show more widespread abnormalities in CAA that represent the combined effects of tissue pathology (e.g., white matter lesions and microinfarctions) and its consequences such as demyelination and axonal degeneration.38 In CAA patients a whole-brain measure of mean apparent diffusion coefficient (ADC) may correlate better with cognitive impairment than other MRI markers.39

Altered vascular function has recently been demonstrated in humans with CAA.40 In this pilot study 11 CAA patients presenting with stroke or memory symptoms, and diagnosed as having probable CAA using the validated Boston Criteria,18 were compared to 9 healthy controls with similar ages and distributions of vascular risk factors. Evoked blood flow velocity in the posterior cerebral artery in response to a visual stimulation task was measured by transcranial Doppler ultrasound and was reduced in the CAA cases compared to controls (Figure 2). Among CAA patients lower evoked flow velocity response correlated with a higher prevalence of MRI white matter lesions and MRI microbleeds. These data are consistent with observations in a mouse model25 with the exception that in humans, in contrast to the animals, there was little effect of CAA on the evoked response to CO2, measured in the middle cerebral artery. The reason for the differential effects of CAA on visual evoked flow in the posterior cerebral artery, compared to CO2 evoked flow in the middle cerebral artery, could not be determined but could reflect relatively less CAA involvement in the middle cerebral artery territory compared to the posterior cerebral artery territory, or the different molecular mechanisms for vasodilation.40

Figure 2
Examples of visual evoked flow in the posterior cerebral artery (PCA) in a 77 year old control subject and a 73 year old subject with cerebral amyloid angiopathy (CAA). A 10 Hz flashing checkerboard stimulus was viewed during the “on” ...

Alzheimer’s disease

AD is characterized pathologically by senile plaques, neurofibrillary tangles, and synaptic and neuronal loss. Studies demonstrate that vascular abnormalities also accompany AD, however, even in the absence of concomitant atherosclerotic vascular disease. The most frequent vascular abnormality seen in AD is CAA.41 Recent careful studies of capillary morphology and density suggest that a broader spectrum of vascular abnormalities may accompany AD and may be partly independent of CAA. Some have even proposed that vascular dysfunction is a critical early component of Alzheimer pathology.9

Severe Alzheimer’s pathology is usually accompanied by some degree of CAA.41, 42 These autopsy studies are supported by MRI studies showing that lobar microbleeds, associated with CAA, are frequently present in the brains of persons with AD even though symptomatic lobar ICH is rare.43-45 The pathology of CAA associated with AD shows differences from the pathology of CAA in the absence of AD, with more frequent capillary relative to arterial CAA.41, 42 In one study capillary CAA was predominantly composed of Aβ42 deposits in the glia limitans rather than deposits in the vessel wall, in contrast to arterial CAA in which Aβ40 deposits predominated and typically involved the arterial wall.46 The authors interpreted their data to suggest that capillary CAA has a neuronal origin and travels along peri-capillary interstitial pathways before depositing in the capillary adventitia. Data from a transgenic mouse model suggests that capillary CAA is associated with capillary occlusion and decreased blood flow.24 Other authors have also documented significant arteriolar vascular deposition in addition to capillary deposition, with loss of smooth muscle actin, in AD compared to controls.47 These CAA-related vascular abnormalities may contribute to impaired cognition in AD. In the Honolulu-Asia Aging Study the combined presence of both moderate-severe CAA and AD on autopsy was associated with greater cognitive impairment in life than the presence of AD alone.34

The microvasculature of patients with AD exhibits morphological changes in addition to vascular or perivascular amyloid deposits. Careful autopsy studies show that capillary density, length, and mean diameters are decreased in AD in comparison with similar-age controls, sometimes with segmental narrowing or dilation.48-51 An initial quantitative study of hippocampal capillary characteristics between AD and controls did not find overall differences, but suggested that associations between AD pathology and capillary morphology may be restricted to the hippocampal subregions most affected by AD.52 A subsequent study compared hippocampal CA1 and entorhinal cortex capillary parameters with the regional burden of Alzheimer pathology and found that lower total capillary number and lower mean capillary diameter correlated with higher burden of senile plaques and neurofibrillary tangles.49 Lower mean capillary diameter was independently associated with greater antemortem cognitive disability, as measured by the Clinical Dementia Rating scale, even after controlling for the burden of senile plaques and neurofibrillary tangles.49 Similar observations have recently been published in a transgenic mouse model of AD, where a vascular corrosion cast was produced by intravascular infusion of a resin followed by removal of the intervening tissue, allowing examination of the 3-dimensional architecture of the microvasculature.53 Electron microscopy of the cast showed “holes” of decreased capillary density alternating with regions of increased density of morphologically abnormal capillaries.53

These observations have led some authors to hypothesize that cerebral hypoperfusion is an early phenomenon in AD that induces neuronal dysfunction and injury.9 Indeed, cerebral hypoperfusion is observed in both the early and late stages of AD,54 Although this phenomenon is often attributed to decreased neuronal metabolism or neuronal loss, impaired vascular function may also contribute. Similarly, numerous studies of neuronal activation-associated changes in blood oxygen level dependent (BOLD) response have been interpreted as solely reflecting neuronal function without consideration of possible influences from vascular pathology. There is a relative dearth of physiologic studies in AD that examine the vascular response to other stimuli such as carbon dioxide inhalation. A recent study found that middle cerebral artery evoked flow velocity to carbon dioxide, measured by transcranial Doppler ultrasound, was reduced in AD compared to controls.55 By contrast other blood flow studies have failed to find abnormal vascular reactivity to carbon dioxide in AD, although small sample sizes limit the strength of the conclusions.56, 57

Soluble beta-amyloid and blood vessel function

Experimental data shows that soluble ABeta can cause abnormal vascular reactivity in the absence of vascular deposition or vessel wall dysfunction. These experiments raise the possibility that vascular dysfunction could be an early step in beta-amyloid diseases and could even precede significant ABeta deposition. Application of exogenous ABeta to normal blood vessels ex vivo causes endothelium-dependent vasoconstriction.58, 59 Likewise application of exogenous ABeta, particularly the ABeta-40 species, to the mouse neocortex induces vasoconstriction in vivo.60 Transgenic mice that over-express amyloid precursor protein exhibit reductions in cerebral blood flow at an early age, prior to deposition of ABeta as plaques,61 and display abnormal vascular autoregulation62 and attenuation of functional hyperemia.63 These effects appear to be mediated by endothelial dysfunction with formation of oxygen free radicals58 by NADPH oxidase.64, 65 The finding that soluble ABeta impairs vasodilatory responses in APP-overexpressing animals has recently been questioned, however,25 and the significance of these experimental findings to human pathophysiology is uncertain at present.

Conclusions and Future Directions

Vascular beta-amyloid deposition is a relatively common pathology of aging and is extremely common in person with AD. Beta-amyloid is directly toxic to smooth muscle cells. Damage to the vessel wall caused by ABeta deposits can result in vascular rupture with intracerebral hemorrhage. ABeta-related vascular dysfunction, manifest as impaired vascular responses to stimuli including changes in systemic blood pressure (impaired autoregulation), arterial partial pressure of carbon dioxide and neuronal activity, seems likely on the basis of experimental evidence but remains underexplored in humans. Vascular dysfunction with reduction in blood flow could be the mechanism by which CAA is associated with microinfaction and small cortical infarcts.

There is a need for further studies to address the relationship between vascular function, brain lesions and clinical function including cognition in persons with beta-amyloid diseases including CAA and AD. Given the high prevalence of CAA in AD, studies are urgently needed to determine whether CAA is an active player in producing cognitive decline, or a bystander. These studies will be aided by careful measurement of beta-amyloid disease burden and vascular reactivity.

Thankfully, recent advances in experimental models and human imaging may aid studies of beta-amyloid and its effects on the vasculature by allowing more careful serial assessments of beta-amyloid burden. The development of mouse models with cranial windows that allow serial amyloid imaging, by multiphoton microscopy,66 will enable longitudinal experimental studies of vascular beta-amyloid growth and its determinants. In humans the development of beta-amyloid-binding PET ligands offers, for the first time, the ability to measure regional and global beta-amyloid deposition in a serial longitudinal manner.67-69 Originally validated as a marker of parenchymal amyloid deposition and AD, it is now clear from autopsy studies that Pittsburgh Compound B (PIB)67 also binds to vascular beta-amyloid.70, 71 A small case series suggests that occipital PIB retention is relatively greater in CAA compared to AD, consistent with the known topographical distribution in CAA.72

With improved in vivo measurements of beta-amyloid, careful physiologic investigations of vascular reactivity, and longitudinal study designs, it should be possible to more firmly establish the role of blood vessel function in producing impairment in CAA and AD. The impact of vascular dysfunction on age-related changes in cognition may currently be underestimated. Identification of vascular dysfunction as a significant component of CAA and AD may open up new therapeutic approaches for these currently largely untreatable diseases.

ACKNOWLEDGEMENTS AND FUNDING

Dr. Smith has received funding from the National Institute of Neurological Disorders and Stroke (R01 NS062028). Dr. Greenberg has received funding from the National Institute of Neurological Disorders and Stroke (K24 NS056207, R01 NS042147), National Institute of Aging (R01 AG026484, R01 AG021084) and Alzheimer’s Association. The authors report no other potential conflicts of interest.

REFERENCES

1. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006;37:345–350. [PubMed]
2. Jin Y-P, Legge S, Ostbye T, Feightner JW, Hachinski V. The reciprocal risks of stroke and cognitive impairment in an elderly population. Alzheimer’s & Dementia. 2006;2:171–178. [PubMed]
3. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–2204. [PubMed]
4. Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci. 2004;226:13–17. [PubMed]
5. Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, Mungas D, Reed BR, Kramer JH, Decarli CC, Weiner MW, Vinters HV. Cognitive impact of subcortical vascular and Alzheimer’s disease pathology. Ann Neurol. 2006;60:677–687. [PMC free article] [PubMed]
6. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813–817. [PubMed]
7. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer’s disease pathology, and memory function in older persons. Ann Neurol. 2007;62:59–66. [PubMed]
8. Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D, Nelson J, Hardman J, Masaki K, Vogt MR, Launer L, White LR. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol. 2005;57:98–103. [PubMed]
9. de la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184–190. [PubMed]
10. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35:2616–2619. [PubMed]
11. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913–922. [PubMed]
12. Saido TC, Iwata N. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer’s disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res. 2006;54:235–253. [PubMed]
13. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol. 2008;18:253–266. [PubMed]
14. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489–1499. [PMC free article] [PubMed]
15. Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci. 2005;8:977–979. [PubMed]
16. Smith EE, Eichler F. Cerebral amyloid angiopathy and lobar intracerebral hemorrhage. Arch Neurol. 2006;63:148–151. [PubMed]
17. Jellinger K. Cerebrovascular amyloidosis with cerebral hemorrhage. J Neurol. 1977;214:195–206. [PubMed]
18. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537–539. [PubMed]
19. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18:311–324. [PubMed]
20. Herzig MC, Van Nostrand WE, Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol. 2006;16:40–54. [PubMed]
21. Vinters HV, Secor DL, Read SL, Frazee JG, Tomiyasu U, Stanley TM, Ferreiro JA, Akers MA. Microvasculature in brain biopsy specimens from patients with Alzheimer’s disease: an immunohistochemical and ultrastructural study. Ultrastruct Pathol. 1994;18:333–348. [PubMed]
22. Wang Z, Natte R, Berliner JA, van Duinen SG, Vinters HV. Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid beta proteins to human cerebral microvessel and aortic smooth muscle cells. Stroke. 2000;31:534–538. [PubMed]
23. Mok SS, Losic D, Barrow CJ, Turner BJ, Masters CL, Martin LL, Small DH. The beta-amyloid peptide of Alzheimer’s disease decreases adhesion of vascular smooth muscle cells to the basement membrane. Journal of Neurochemistry. 2006;96:53–64. [PubMed]
24. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg S, Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging. 2008 [PubMed]
25. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain. 2007;130:2310–2319. [PubMed]
26. Cadavid D, Mena H, Koeller K, Frommelt RA. Cerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol. 2000;59:768–773. [PubMed]
27. Olichney JM, Hansen LA, Hofstetter CR, Lee JH, Katzman R, Thal LJ. Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol. 2000;57:869–874. [PubMed]
28. Haglund M, Passant U, Sjobeck M, Ghebremedhin E, Englund E. Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int J Geriatr Psychiatry. 2006;21:681–687. [PubMed]
29. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 2002;33:1986–1992. [PubMed]
30. Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord. 2002;14:161–166. [PubMed]
31. Gray F, Dubas F, Roullet E, Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol. 1985;18:54–59. [PubMed]
32. Imaoka K, Kobayashi S, Fujihara S, Shimode K, Nagasaki M. Leukoencephalopathy with cerebral amyloid angiopathy: a semiquantitative and morphometric study. J Neurol. 1999;246:661–666. [PubMed]
33. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) Lancet. 2001;357:169–175. [PubMed]
34. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002;58:1629–1634. [PubMed]
35. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J, Greenberg SM. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology. 2004;63:1606–1612. [PubMed]
36. Holland CM, Smith EE, Csapo I, Gurol ME, Brylka DA, Killiany RJ, Blacker D, Albert MS, Guttmann CR, Greenberg SM. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke. 2008;39:1127–1133. [PMC free article] [PubMed]
37. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathology. 2006;16:30–39. [PubMed]
38. Salat DH, Smith EE, Tuch DS, Benner T, Pappu V, Schwab KM, Gurol ME, Rosas HD, Rosand J, Greenberg SM. White matter alterations in cerebral amyloid angiopathy measured by diffusion tensor imaging. Stroke. 2006;37:1759–1764. [PubMed]
39. Viswanathan A, Patel P, Rahman R, Nandigam RN, Kinnecom C, Bracoud L, Rosand J, Chabriat H, Greenberg SM, Smith EE. Tissue microstructural changes are independently associated with cognitive impairment in cerebral amyloid angiopathy. Stroke. 2008;39:1988–1992. [PMC free article] [PubMed]
40. Smith EE, Vijayappa M, Lima F, Delgado P, Wendell L, Rosand J, Greenberg SM. Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology. 2008;71:1424–1430. [PMC free article] [PubMed]
41. Attems J, Jellinger KA, Lintner F. Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathologica. 2005;110:222–231. [PubMed]
42. Attems J, Jellinger KA. Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology--a pilot study. Acta Neuropathologica. 2004;107:83–90. [PubMed]
43. Atri A, Locascio JJ, Lin JM, Yap L, Dickerson BC, Grodstein F, Irizarry MC, Growdon JH, Greenberg SM. Prevalence and effects of lobar microhemorrhages in early-stage dementia. Neurodegener Dis. 2005;2:305–312. [PubMed]
44. Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, George-Hyslop P, Rogaeva E, Black SE. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol. 2008;65:790–795. [PubMed]
45. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology. 2006;66:1356–1360. [PubMed]
46. Attems J, Lintner F, Jellinger KA. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol (Berl) 2004;107:283–291. [PubMed]
47. Stopa EG, Butala P, Salloway S, Johanson CE, Gonzalez L, Tavares R, Hovanesian V, Hulette CM, Vitek MP, Cohen RA. Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke. 2008;39:814–821. [PubMed]
48. Buee L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM. Pathological alterations of the cerebral microvasculature in Alzheimer’s disease and related dementing disorders. Acta Neuropathol. 1994;87:469–480. [PubMed]
49. Bouras C, Kovari E, Herrmann FR, Rivara CB, Bailey TL, von Gunten A, Hof PR, Giannakopoulos P. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol. 2006;65:235–244. [PubMed]
50. Kitaguchi H, Ihara M, Saiki H, Takahashi R, Tomimoto H. Capillary beds are decreased in Alzheimer’s disease, but not in Binswanger’s disease. Neurosci Lett. 2007;417:128–131. [PubMed]
51. Fischer VW, Siddiqi A, Yusufaly Y. Altered angioarchitecture in selected areas of brains with Alzheimer’s disease. Acta Neuropathol. 1990;79:672–679. [PubMed]
52. Bell MA, Ball MJ. Morphometric comparison of hippocampal microvasculature in ageing and demented people: diameters and densities. Acta Neuropathol. 1981;53:299–318. [PubMed]
53. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease. Proc Natl Acad Sci U S A. 2008;105:3587–3592. [PMC free article] [PubMed]
54. Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, Albert MS. Preclinical prediction of Alzheimer’s disease using SPECT. Neurology. 1998;50:1563–1571. [PubMed]
55. Bar KJ, Boettger MK, Seidler N, Mentzel HJ, Terborg C, Sauer H. Influence of galantamine on vasomotor reactivity in Alzheimer’s disease and vascular dementia due to cerebral microangiopathy. Stroke. 2007;38:3186–3192. [PubMed]
56. Jagust WJ, Eberling JL, Reed BR, Mathis CA, Budinger TF. Clinical studies of cerebral blood flow in Alzheimer’s disease. Ann N Y Acad Sci. 1997;826:254–262. [PubMed]
57. Yamaguchi F, Meyer JS, Yamamoto M, Sakai F, Shaw T. Noninvasive regional cerebral blood flow measurements in dementia. Arch Neurol. 1980;37:410–418. [PubMed]
58. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. beta-Amyloidmediated vasoactivity and vascular endothelial damage. Nature. 1996;380:168–171. [PubMed]
59. Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, Mullan M. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Annals of the New York Academy of Sciences. 2002;977:65–76. [PubMed]
60. Niwa K, Carlson GA, Iadecola C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. Journal of Cerebral Blood Flow & Metabolism. 2000;20:1659–1668. [PubMed]
61. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiology of Disease. 2002;9:61–68. [PubMed]
62. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. American Journal of Physiology - Heart & Circulatory Physiology. 2002;283:H315–323. [PubMed]
63. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:9735–9740. [PMC free article] [PubMed]
64. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci. 2005;25:1769–1777. [PubMed]
65. Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, Carlson G, McEwen BS, Iadecola C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A. 2008;105:1347–1352. [PMC free article] [PubMed]
66. Robbins EM, Betensky RA, Domnitz SB, Purcell SM, Garcia-Alloza M, Greenberg C, Rebeck GW, Hyman BT, Greenberg SM, Frosch MP, Bacskai BJ. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. Journal of Neuroscience. 2006;26:365–371. [PubMed]
67. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319. [PubMed]
68. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–2663. [PubMed]
69. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O’Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718–1725. [PubMed]
70. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431–434. [PubMed]
71. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:2607–2615. [PubMed]
72. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229–234. [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...